Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Dr Edward Garon, Ms Kelly Goodwin, Ms Tara Plues and Dr Anne Tsao, including the following topics:
Introduction (0:00) Key Lung Cancer Diagnostic Tools (7:40) Targeted Therapy for Localized Disease (18:05) Targeted Therapy for Metastatic Disease (33:01) Immunotherapy for Localized Disease (1:31:18) Immunotherapy for Metastatic Disease (1:53:36) NCPD information and select publications

Featuring perspectives from Ms Jamie Carroll, Dr Sara Hurvitz, Ms Kelly Leonard and Dr Hope Rugo, including the following topics:
Introduction (0:00) High-Risk Localized ER-Positive, HER2-Negative Breast Cancer (5:07) ER-Positive Metastatic Breast Cancer (28:06) Localized HER2-Positive Breast Cancer (49:15) Metastatic HER2-Positive Breast Cancer (1:07:06) Localized Triple-Negative Breast Cancer (TNBC); Role of Immunotherapy (1:30:08) Metastatic TNBC (1:49:41) CME information and select publications

Featuring perspectives from Ms Kathy Burns, Dr Robert Dreicer, Dr Sandy Srinivas and Mr Ronald Stein, including the following topics:
Introduction (0:00) PSA-Only Recurrence (M0 Disease) (10:45) Metastatic Hormone-Sensitive Prostate Cancer (35:07) Metastatic Castration-Resistant Prostate Cancer (BRCA Wild Type) (48:48) Metastatic Castration-Resistant Prostate Cancer (BRCA Mutant) (1:10:42) CME information and select publications

Featuring perspectives from Dr Ross Camidge, including the following topics:
Introduction: First-line systemic treatment; brain metastases (0:00) Case: A woman in her early 60s with squamous NSCLC metastatic to tbe brain and an ALK rearrangement; PD-L1 TPS 70% — Spencer Henick Bachow, MD (20:30) Case: A man in his early 70s with localized NSCLC with an ALK rearrangement and significant comorbidities — Sunil Gandhi, MD (24:44) Case: A woman and heart transplant recipient in her mid 70s with metastatic NSCLC with a KRAS G12C mutation; PD-L1 TPS 20% — Mamta Choksi, MD (30:26) Case: A woman in her late 70s with metastatic NSCLC and a MET exon 14 skipping mutation — Jennifer L Dallas, MD (36:01) Case: A woman in her late 60s with metastatic NSCLC and a HER2 exon 19 mutation pathogenic variant; PD-L1 TPS 15% — Rajni Sinha, MD, MRCP (41:43) Case: A man in his early 30s with metastatic NSCLC and an NTRK fusion; PD-L1 TPS 10% — Daniel R Carrizosa, MD, MS (46:09) Treatment for Patients with ROS1 Fusions (48:34) RET Fusions in Lung Cancer (52:38) BRAF Mutations (54:20) NRG Fusions (55:31) CME information and select publications

Featuring perspectives from Drs Tanios Bekaii-Saab and Philip Philip, including the following topics: 
Introduction (0:00) Treatment for Hepatocellular Carcinoma (14:52) Management of Biliary Tract Cancers (36:08) Clinical Decision-Making for Patients with Pancreatic Cancer (47:28) CME information and select publications 

Featuring an interview with Dr David O'Malley, including the following topics:
Efficacy and safety data with mirvetuximab soravtansine for ovarian cancer (OC) from the SORAYA trial (0:00) Potential integration of mirvetuximab soravtansine into clinical practice; biologic rationale for and mechanism of action of upifitamab rilsodotin in therapy for OC (6:30) Rationale for using tumor treating fields in combination with paclitaxel for OC; efficacy data with tumor treating fields for thoracic mesothelioma and glioblastoma multiforme (12:45) Ongoing work on quantitative tests to identify patients most likely to benefit from PARP inhibitors; real-world treatment patterns in OC (21:27) Single-agent neoadjuvant niraparib; emerging data with niraparib/bevacizumab and potential integration into treatment algorithms (28:46) PARP inhibitors in patients with BRCA wild-type OC; design, similarities and differences from the PRIME and PRIMA trials of maintenance niraparib (36:02) Ongoing MONO-OLA1 trial of olaparib with and without bevacizumab as up-front treatment for OC; final overall survival and second progression-free survival data from the SOLO-3 trial (42:28) CME information and select publications